Abstract: Nucleoside analogues comprising a citrate group can be used to obtain immunogens designed to produce antibodies having an affinity for triphosphorylated nucleosides. Such antibodies are useful for implementing sensitive immunologic assays for triphosphorylated nucleoside derivatives.

Abstract: Nucleoside analogues comprising a citrate group can be used to obtain immunogens designed to produce antibodies having an affinity for triphosphorylated nucleosides. Such antibodies are useful for implementing sensitive immunologic assays for triphosphorylated nucleoside derivatives.

Abstract: The invention relates to an electric arc welding torch comprising a torch body having an electrode holder (3) and a nozzle (4), said nozzle (4) being formed with at least one nozzle partition (2) having an internal surface (2a) and an external surface (2b), characterized in that at least one supplemental partition (8) extends along at least one portion of the internal surface (2a) and/or external surface (2b) of the nozzle partition (2), in that one of said partitions (2, 8) is electrically conductive and in that the other of said partitions (2, 8) is electrically insulating and the use of such a torch in an electric arc welding or cutting process under a protective gas, particularly a TIG, MIG or MAG welding process.

Abstract: The invention provides biologically active compounds of the formula: ##STR1## where R.sub.1 is a light-emitting moiety and R.sub.7 is a peptide of between 2 and 200 amino acids. X is selected from the group including .dbd.O, .dbd.S, --OH, .dbd.C.tbd.O, .dbd.NH, --H, --OR, --NR, --R, --R.sub.3 R.sub.4, wherein each R, R.sub.4 and R.sub.3, independently, is H or a C1-C6 branched or unbranched, substituted or unsubstituted, alkyl. The compounds are both biologically active and optically detectable. The peptide is chemically attached to the light-emitting moiety at an amino acid position which is not involved in binding to the peptide's receptor. In this way, the peptide's affinity for its receptor is not significantly decreased, and the compound retains high biological activity and can be easily detected using standard optical means.

Abstract: Light-emitting compounds of the formula: ##STR1## where R.sub.1 is a light-emitting moiety and R.sub.2 is a somatostatin-based peptide featuring a first amino acid sequence -Phe-Phe-Trp-Lys-Thr- or (SEQ ID NO:1) or -Phe-Phe-D-Trp-Lys-Thr-. The peptide is linked at a first amino acid position to (C-X), and the light-emitting compound exhibits substantial biological activity in the presence of a receptor having affinity for somatostatin-based peptides.

Abstract: Light-emitting compounds of the formula: ##STR1## where R.sub.1 is a light-emitting moiety and R.sub.2 is a somatostatin-based peptide featuring a first amino acid sequence --Phe--Phe--Trp--Lys--Thr-- (SEQ ID NO:1) or --Phe--Phe--D--Trp--Lys--Thr--. The peptide is linked at a first amino acid position to (C--X), and the light-emitting compound exhibits substantial biological activity in the presence of a receptor having affinity for somatostatin-based peptides.